|
|
Cinacalcet for hyperparathyroidism trial results published in NEJM. |
|
NEJM: Results Forty-three percent of the cinacalcet group reached the primary end point, as compared with 5 percent of the placebo group (P<0.001). Overall, mean parathyroid hormone values decreased 43 percent in those receiving cinacalcet but increased 9 percent in the placebo group (P<0.001). The serum calcium–phosphorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo group (P<0.001). Cinacalcet effectively reduced parathyroid hormone levels independently of disease severity or changes in vitamin D sterol dose.
|
|
|
NEJM: Coronary revascularization better than percutaneous procedures for diabetic patients. |
|
NEJM: Conclusions For patients with diabetes and advanced coronary artery disease, CABG was superior to PCI in that it significantly reduced rates of death and myocardial infarction, with a higher rate of stroke.
|
|
Tolvaptan for polycystic kidney disease trial published in NEJM. |
|
NEJM: Conclusions. Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events
|
|
Chicago area facilities board rejects plans for several new dialysis units from FMC and US Renal |
|
Crain's Chicago Business: Suburban projects from two dialysis companies received the cold shoulder on Wednesday from the Illinois Health Facilities and Services Review Board.
|
|
ASN Kidney News - Kidney Week edition |
|
ASN: Here is the ASN Kidney News summary of the annual meeting.
|
|
|
|
|
<< Start < Prev 251 252 253 254 255 256 257 258 259 260 Next > End >>
|
|
Page 255 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
